Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  exemestane
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 42 for your search:
Start Over
Aromatase Inhibitor Clinical Trial
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 40 to 70
Sponsor: NIGMS
Protocol IDs: 0412-14, UO1-GM61373-06, NCT00228956
Aromasin® Non-Interventional Study Of Early Invasive Breast Cancer Patients In China
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A5991093, NRA5990043, NCT01176916
Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab
Phase: Phase IV
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: iOM-12293, NCT02248571
Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients
Phase: Phase IV
Type: Supportive care, Treatment
Status: Active
Age: 18 and over, premenopausal
Sponsor: Other
Protocol IDs: OFSS, NCT02440230
Efficacy and Safety of TAC and Exemestane as Neoadjuvant Chemotherapy in the Postmenopausal Women With Breast Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: Postmenopausal
Sponsor: Other
Protocol IDs: TENBC, NCT01648608
Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 70
Sponsor: Other
Protocol IDs: CDR0000635986, COL-MNEMOSYNE, 2007-12, INCA-RECF0899, EUDRACT-2008-003620-32, MNEMOSYNE, NCT00893061
Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: Postmenopausal
Sponsor: Other
Protocol IDs: SHBCC0701, NCT00902954
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
Phase: Phase III
Type: Health services research, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02623, CDR0000692475, SWOG-S1007, S1007, U10CA180888, U10CA032102, NCT01272037
DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: DETECT III, 2010-024238-46, NCT01619111
Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With Poor Prognosis, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving 3 Years of Adjuvant Hormone Therapy
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UNIRAD, 2012-003187-44, UC-0140/1208, NCT01805271
Exemestane With or Without Entinostat in Treating Postmenopausal Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2014-00746, ECOG-E2112, E2112, U10CA180820, U10CA021115, NCT02115282
Detect V / CHEVENDO (Chemo vs. Endo)
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and ove
Sponsor: Other
Protocol IDs: D-V, 2014-002249-22, NCT02344472
Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over, postmenopausal
Sponsor: Pharmaceutical / Industry
Protocol IDs: GIM16-FEVEX, NCT02404051
A Trial of AZD4547 for Breast Cancer That is Oestrogen Receptor Positive and Has Got Worse Despite Having Anastrozole or Letrozole
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 25 and over
Sponsor: Other
Protocol IDs: C/23/2011, 2011-000454-32, NCT01791985
Phase Ib/II Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of ER+ Her2- Advanced Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLEE011X2106, NCT01857193
Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C31001, NCT02049957
Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000595712, SINGAPORE-NCC0706, NCC0706, NCT00687648
Study of Aspirin and Exemestane as Adjuvant Treatment in Breast Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 50 to 80
Sponsor: Other
Protocol IDs: CH-BC-011, NCT01431053
Ruxolitinib in Estrogen Receptor Positive Breast Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 02112, NCT01594216
Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Metronomic Therapy, NCT01924078
Exemestane and Cyclophosphamide for Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: S13-00761, NCT01963481
Bevacizumab Plus Paclitaxel Optimization Study With Interventional Maintenance Endocrine Therapy in Advanced or Metastatic ER-positive Human Epidermal Growth Factor Receptor 2(HER2)-Negative Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 20 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: JBCRG-M04, NCT01989780
A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IRST174.08, 2012-003510-13, NCT02000375
Start Over